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a  b  s  t  r  a  c  t
A  remarkable  and  intriguing  challenge  for the  modern  medicine  consists  in the  development  of alterna-
tive  therapies  to  avoid  the  problem  of  microbial  resistance.  The  cationic  antimicrobial  peptides  present
a promise  to be used  to develop  more  efﬁcient  drugs  applied  to human  health.  The  in  silico  analysis  of
genomic  databases  is  a  strategy  utilized  to predict  peptides  of therapeutic  interest.  Once  the  main  antimi-
crobial  peptides’  physical–chemical  properties  are  already  known,  the  correlation  of those  features  to
search on these  databases  is  a tool to shorten  identifying  new  antibiotics.  This study reports  the  iden-
tiﬁcation  of  antimicrobial  peptides  by theoretical  analyses  by  scanning  the  Paracoccidioides  brasiliensis
transcriptome  and the human  genome  databases.  The  identiﬁed  sequences  were  synthesized  and  inves-
tigated  for hemocompatibility  and  also  antimicrobial  activity.  Two  peptides  presented  antifungal  activity
against  Candida  albicans.  Furthermore,  three  peptides  exhibited  antibacterial  effects  against  Staphylococ-
cus  aureus  and  Escherichia  coli;  ﬁnally  one  of  them  presented  high  potential  to  kill  both  pathogens  with
superior  activity  in comparison  to chloramphenicol.  None  of  them  showed  toxicity  to mammalian  cells.
In silico  structural  analyses  were  performed  in  order  to  better  understand  function–structure  relation,
clearly  demonstrating  the  necessity  of  cationic  peptide  surfaces  and  the  exposition  of  hydrophobic  amino
acid residues.  In  summary,  our  results  suggest  that  the  use of  computational  programs  in  order  to  identify
and evaluate  antimicrobial  peptides  from  genomic  databases  is  a remarkable  tool  that  could  be  used  to
abbreviate  the  search  of  peptides  with  biotechnological  potential  from  natural  resources.
©  2012  Elsevier  Inc.  Open access under the Elsevier OA license.. Introduction
The growing number of the pathogen’s resistance mechanisms
o conventional drugs signiﬁcantly increased in the last decade, in
art because of the increase of the immune-compromised patients
5]. In some cases due to the resistance problem, only few drugs
resent the potency necessary to treat these opportunistic infec-
ions. Unfortunately, some of these drugs, such as amphotericin
, have the disadvantage of excessive toxicity, which could limit
ts use by patients receiving other therapies with toxic drugs, i.e.
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aboratório de Biologia Molecular, Campus Darcy Ribeiro, Asa Norte, Brasília – DF
0910-900, Brazil. Tel.: +55 61 33072423; fax: +55 61 33498411.
E-mail address: msueliunb@gmail.com (M.S.S. Felipe).
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Open access under the Elsevier OA license.anticancer therapy [16]. The development of alternative antibiotic
therapies able to circumvent this problem is one of the intriguing
challenges of the modern medicine. For this purpose, antimicrobial
peptides represent a promise to be used as antifungal and bacteri-
cidal agents since episodes of natural resistance to these peptides
are not frequent [2,18,23].
Antimicrobial peptides can be found in all forms of life, from bac-
teria and fungi to plants, invertebrates and vertebrates [23]. They
can be produced from secondary metabolites or, as most of them,
encoded by genes conserved throughout evolution [3,44].  Despite
some exceptions [32], usually, these peptides have the common
features of being present on a cationic surface and also forming
amphipathic structures [34,37].
Among the strategies used to identify these peptides, the tech-
nique to predict peptide sequences directly from genomic or
transcriptome databases is currently used [19]. The genomic and
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ranscriptome databases are valuable sources to identify gene
equences involved in the biosynthesis of antibiotics [4]. The in sil-
co analysis of protein sequences or direct into the genes databases
re strategies used to predict peptides of therapeutic interest [31].
he search for peptides using this strategy is performed by using
ophisticated computational programs that scans the databases,
orrelating the antimicrobial peptide features previously described
n the literature on the amino acid sequences. Since the main char-
cteristics of antimicrobial peptides are already known, the pursuit
f these similarities in silico in these databases is a tool to shorten
he identiﬁcation and selection of new antibiotics [14,17].
In order to certify the in silico identiﬁed peptides, the selected
equences must be synthesized by chemical synthesis and evalu-
ted in vitro against selected microorganisms aiming to explore the
ntimicrobial potential [4,23].  Besides, knowing these sequences,
t is also possible to make chemical variations in their amino acid
esidues, changing the primary structures in order to improve their
ntimicrobial activity [31].
The present study reports on the use of novel software to iden-
ify antimicrobial peptide sequences on the fungus Paracoccidioides
rasiliensis transcriptome and on the human genome databases.
he selected sequences were biochemically synthesized and in vitro
ested against fungi and bacteria. Furthermore, in silico structural
nalyses were also conducted.
. Materials and methods
.1. Peptides selection
.1.1. In silico identiﬁcation of antimicrobial peptides
The peptides were obtained from genome databank by using
 script that takes in consideration peptide length, total charge
urface and hydrophobic moment (data not published). Among
undred peptides, 13 were selected since it ﬁtted to proper-
ies described in APD2 databank as antimicrobial peptides [47].
he criteria used to design this software took into considera-
ion some antimicrobial characteristics such as the presence of
ositively charged amino acid residues, low molecular weight,
nd the balance between cationic charge and hydrophobicity.
he databases used to identify these sequences were the human
enome (http://genome.gov) and transcriptome of the human
athogenic fungus P. brasiliensis (https://dna.biomol.unb.br/Pb/).
everal potential antimicrobial peptide sequences were identiﬁed
n both databases and four of them, two from each database, based
n better antimicrobial characteristics, were selected and chemi-
ally synthesized.
.1.2. Peptides synthesis
The peptides were synthesized by the 9-ﬂuoroenylmethoxy-
arbonyl technique [22] using an automated bench top simulta-
eous multiple solid-phase peptide synthesizer (PSSM 8 system;
himadzu, Tokyo, Japan). The synthesized peptides were then
e-puriﬁed with a semi-preparative reverse-phase C-18 (5 m,
00A, Vydac 218TP510, Hesperia, USA) in a high-pressure liquid
hromatography (HPLC) system (Shimadzu Co., Japan). The HPLC
ractions were eluted in 60 min  in linear gradient water and ace-
onitrile (JT Baker, Mexico), both containing 0.1% triﬂuoroacetic
cid (TFA, JT Baker, Mexico). RP-HPLC experiments were moni-
ored at two different wavelengths (216 and 280 nm). The purity
f peptides was assessed by analysis of the molecules present
n the fractions using mass spectrometry MALDI-TOF/TOF Ultra-
ex II (Bruker Daltonics, Germany). The puriﬁed peptides were
yophilized and stored at −70 ◦C until used. The peptides were iden-
iﬁed as P1 and P4 from the human genome and P2 and P3 from P.
rasiliensis transcriptome. 37 (2012) 301–308
2.2. In vitro hemocompatibility study
Fresh heparinized blood of Swiss mice was used to investigate
the in vitro hemolytic activity of the peptides according to Italia
and collaborators [26] with minor modiﬁcations. The red blood
cells (RBCs) were obtained by centrifugation of the whole blood
at 3000 rcf for 15 min. The supernatant was  discarded and the RBCs
were washed thrice with saline solution (NaCl 0.9%). The work-
ing solution was prepared containing three parts of RBCs mixed
with 11 parts of saline solution. For the assay, a dilution of 100 l
of the working solution to 1 ml  of the samples was prepared. The
treatment groups were the RBCs (working solution) mixed with: (a)
distilled water (positive control, 100% hemolysis); (b) saline solu-
tion (negative control, minimum hemolysis); and (c) samples of
the peptides P1, P2, P3, or P4 at concentrations of 64, 128, and
256 g ml−1. The samples were incubated at 37 ◦C for 6 h and at
time intervals of 30 min, 3 h and 6 h, they were centrifuged at
3000 rcf for 15 min. The supernatant was collected and maintained
for 30 min  at room temperature to oxidize hemoglobin and the
absorbance of Oxy-Hb was  determined by spectrophotometry at
540 nm.  The percentage of hemolysis was  calculated based on the
assumption that 100% RBC lysis resulted from mixing of RBCs with
distilled water.
2.3. Antimicrobial investigation
Antimicrobial activity of the peptides against Gram-positive,
Gram-negative bacteria and fungi was  determined by the broth
microdilution assay in accordance with the methods developed by
the National Committee on Clinical Laboratory Standards (NCCLS)
[11] with some modiﬁcations.
2.4. Antifungal tests
2.4.1. Strains and growth conditions
The human pathogenic fungus P. brasiliensis,  isolates Pb01 and
Pb18, were obtained from the fungi collection of Molecular Biology,
Universidade de Brasília, and cultivated in Brain Heart Infusion cul-
ture medium (Merck, Germany) at 36 ◦C in rotary shaker (220 rpm)
for 5 days before the tests. The Candida albicans clinical isolate was
provided by Sabin Laboratory, Brasília, DF, and was  grown in cul-
ture medium Sabouraud agar (Acumedica, USA) at 37 ◦C overnight
before performing the assay.
2.4.2. Determination of the minimum inhibitory concentration
(MIC)
Two different protocols were used to test the in vitro activity of
the peptides against fungi in order to investigate the inﬂuence of
the incubation time on the assay.
Protocol I was  used to test the peptides fungal activities against
P. brasiliensis and C. albicans. The methodology used to determine
the MICs was  adapted from the antifungal protocol NCCLS [11].
The peptides P1, P2, P3, and P4 were serially diluted from 2 to
256 g ml−1 in culture medium Muller-Hinton for C. albicans and
RPMI1640 for P. brasiliensis.  A 2-fold dilution series of peptides was
prepared and serial dilutions (50 l) were added to 50 l of cell
suspension of C. albicans (2 × 104 viable cells ml−1) or P. brasilien-
sis (2 × 105 viable cells ml−1) in 96-well microtiter polypropylene
plates (Corning). The plates were incubated at 36 ◦C during 24 h for
C. albicans and 6 days for P. brasiliensis.  The differences in the incu-
bation time and the smaller amount (10 times) of cells used for C.
albicans than for P. brasiliensis were due to the growth characteris-
tic differences observed for each fungus. The growth inhibition was
determined by measuring absorbance at 595 nm with a Model 450
Microplate Reader (Bio-Rad) after the incubation times. The low-
est concentration of peptide that completely inhibited growth of
ptides
t
M
o
b
T
w
s
t
t
(
p
U
(
4
p
g
e
t
M
o
t
U
u
2
2
p
a
t
i
t
2
t
t
t
d
(
t
i
w
p
t
2
v
p
[
t
5
p
w
e
t
w
w
m
a
o
aA.C. Amaral et al. / Pe
he fungi was deﬁned as the minimal inhibitory concentration. The
ICs were calculated by the average values obtained in triplicates
n three independent measurements.
Protocol II was used only for P. brasiliensis,  in which the incu-
ation time was 12 h and the methodology was  adapted from
ravassos and collaborators [42]. The peptides P1, P2, P3, and P4
ere serially diluted from 16 to 500 g ml−1 in phosphate buffer
aline (PBS, pH 7.2). A 2-fold dilution series (100 l) were added
o 100 l of 2 × 104 viable cells of the P. brasiliensis in 500 l plas-
ic tubes. The tubes were incubated at 36 ◦C in rotatory shaker
100 rpm) during 12 h. After this period, 100 l of each tube were
lated in solid medium Brain Heart Infusion (BHI, Acumedia®,
SA) supplemented with 4% (v/v) horse serum (Gibco, USA), 5%
v/v) supernatant of the culture ﬁltrate of the isolate Pb192 and
0 mg  l−1 gentamycin (Schering-Plow, USA). The ﬁltrate was pre-
ared according to methodology described previously [42]. The
rowth of colony-forming units was observed for 21 days. The low-
st concentration of peptide that completely inhibited growth of
he fungi was deﬁned as the minimal inhibitory concentration. The
ICs were calculated by the average values obtained in triplicates
n three independent measurements [36]. The experimental con-
rols used in both protocols were amphotericin B (Sigma–Aldrich,
SA) and for protocol II the killer peptide (KP) as control was  also
sed.
.5. Antibacterial tests
.5.1. Bacterial strains and growth conditions
The antibacterial activity was evaluated against human
athogenic bacteria Escherichia coli ATCC8739 and Staphylococcus
ureus ATCC25923, both obtained from the American Type Cul-
ure Collection (ATCC). Brieﬂy, the bacterial cultures were grown
n Lysogeny Broth (LB) medium, pH 7.0, at 37 ◦C until they reached
he exponential phase.
.5.2. Determination of the antibacterial activity
The method used to study the antibacterial activity of the pep-
ides was based on the broth microdilution assay. The culture for
he assay was prepared by diluting 1:11 the bacteria obtained on
he exponential phase. The peptides P1, P2, P3, and P4 were serially
iluted from 2 to 256 g ml−1 in LB medium. A 2-fold dilution series
100 l) were added to 10 l of approximately 5 × 106 CFU of bac-
eria in each well of a 96-well polypropylene plate. The plates were
ncubated for 4 h at 37 ◦C and the peptides antibacterial activities
ere observed in every 30 min  by measuring the absorbance in a
late reader (Bio-Rad 680 Microplate Reader) at 595 nm.  The con-
rols utilized were distilled water and chloramphenicol 60 g ml−1.
.6. Molecular modeling
Primaries sequences were obtained from initial selection pre-
iously described in this section. All of them being of synthetic
eptide amidate. PSI-BLAST was used for templates data mining
48]. For P1 and P2 peptides models, it was possible to obtain
emplates by homology method (pdb: 2jx6 and 1id3), showing
5 and 88% of identity respectively [45,48].  Fifty models for each
eptide were constructed by using Modeller v9.8. These models
ere evaluated by satisfaction of spatial restraints, considering
nergy minimization, which was conducted by default parame-
ers. P3 and P4 do not show signiﬁcant homology to any peptide
ith structures previously elucidated. For these last I-Tasser server
as utilized in construct models combining ab initio and threading
ethodologies. Models validation was realized by using C-score
nd TM-score parameters. C-score is based on the signiﬁcance
f threading template alignment and varies between −5 and 2
nd positive values indicate better quality of predicted models. 37 (2012) 301–308 303
TM-score standards were used for measuring similarities between
two structures, which are usually used to measure the accuracy
of model when the native structures are known. Models with
TM-score higher than 0.5 indicate a model with correct topology.
Predicted P1, P2, P3 and P4 tridimensional models were evaluated
using PROCHECK for analysis of stereochemical quality. In addition
RMSDs were calculated for superposition of C traces and back-
bones onto the templates structures through the program 3DSS.
The peptides structures were visualized and analyzed on Delano
Scientiﬁc’s PYMOL (http://pymol.sourceforge.net/).
2.7. Statistical analysis
All data were analyzed by Student’s test and ANOVA. P values
below 0.05 were considered signiﬁcant.
3. Results
3.1. In silico identiﬁcation of antimicrobial peptides
Using a software designed by us to identify antimicrobial pep-
tide sequences in the transcriptome and genome databases, it was
possible to abbreviate and ﬁnd out the search for these molecules.
This software was  used to scan the transcriptome of the human
pathogenic fungus P. brasiliensis and the human genome to ﬁnd
amino acids sequences that presented antimicrobial characteris-
tics according to algorithms previously designed to identify, among
other characteristics, the presence of speciﬁc amino acids residues.
Data presented here are part of a research line including the
sequencing of the P. brasiliensis transcriptome focusing on further
molecular drug targets identiﬁcation. In this view, P. brasiliensis
database was  explored in order to ﬁnd novel antimicrobial pep-
tides since few is known about the presence of such compounds in
this species. Nevertheless in last few years the presence of antimi-
crobials in pathogens has been widely described due to necessity of
pathogenic fungi to develop defense mechanisms to compete and
survive to the presence of other microorganisms [17,21].
After performing the scan on the genomic databases, some
possible amino acids sequences with the desired characteristics
previously deﬁned were identiﬁed. Of these, we selected the four
most promising that contained the higher algorithms score previ-
ously developed (data not shown) and also that have higher ﬁtness
to APD2 best scores for antimicrobial peptides [47], such as pres-
ence of positively charged amino acid residues, peptide length
and the balance between cationic charge and hydrophobicity. They
were then chemically synthesized, puriﬁed, sequences conﬁrmed
by MALD-TOF/TOF and investigated in vitro for hemocompatibility
and antimicrobial activity. The selected amino acid sequences were
submitted to a Blast analysis and no signiﬁcant hits were identiﬁed
for the peptides P1 and P4 from the human genome. Similarities
were found for the peptides P2 and P3, from the P. brasiliensis
transcriptome, for the histone h2 and a ribososomal protein S12,
respectively, of several fungi species. Nevertheless, no identity was
observed for peptides reported here with antimicrobial peptides
classes previously described.
3.2. In vitro hemocompatibility study
In order to investigate whether the peptides could cause some
hemolytic effect, they were incubated for 0.5 h, 3 h, and 6 h with
the red blood cells (RBCs) in saline solution (NaCl 0.9%) phosphate
buffer saline (pH 7.2). The pattern of hemolysis resulting from the
incubation of RBCs with the peptides P1, P2, P3, and P4, are depicted
in Fig. 1. Since no differences were observed between peptide con-
centrations tested (64, 128, and 256 g ml−1) or between the times
304 A.C. Amaral et al. / Peptides 37 (2012) 301–308
F bation with the peptides P1, P2, P3, or P4 at concentration of 256 g ml−1 for 6 h. The C−:
s r, used as positive control (100% of lysis). *P ≤ 0.05.
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Fig. 2. The inhibitory activity on bacterial cell growth induced by the peptides P1,
T
T
Pig. 1. The in vitro percentage of red blood cells (RBCs) lysis pattern following incu
aline  solution, pH 7.2 used as negative control (minimum lysis); C+: distilled wate
bserved (0.5 h, 3 h, 6 h), only results for the highest concentra-
ion (256 g ml−1) and for the most extended incubation time (6 h)
re presented here. The distilled water was used as positive con-
rol and considered to cause 100% hemolysis due to the rupture
aused by the osmotic pressure on the RBCs. The saline solution was
sed as negative control which causes a minimum osmotic pres-
ure across the cell membrane of RBCs maintaining the integrity
f cell membrane. None of the peptides presented hemolytic effect
hen compared to the positive control. The peptides P3 and P4,
hat presented the higher levels of hemolysis, did not show signiﬁ-
ant difference even when compared with the saline solution. The
ata therefore, indicate that the predicted peptides did not cause
BCs lysis.
.3. Antimicrobial investigation
.3.1. Antifungal tests
The peptides P1, P2, P3 and P4 were tested in order to investigate
he in vitro antimicrobial activity against the human pathogenic
ungi C. albicans and P. brasiliensis isolates Pb01 and Pb18. Two dif-
erent protocols were used, which differ from each other on the
ncubation time used, as described in the Materials and Methods
ection. Table 1 shows that two of four selected peptides exhibited
ntifungal activity against C. albicans, determined by the mini-
um inhibitory concentration (MIC) of 82 M and 133 M for
eptides P1 and P2, respectively. The MIC  indicates the required
mount of the active compound to kill or inhibit the growth of the
icroorganisms. The control for the assay used was amphotericin
, MIC  0.5 M.  Another control used against this pathogen was the
iller peptide (KP), which presented MIC  value of 1 M.  Moreover,
he four peptides tested exerted no detectable antifungal activity
gainst P. brasiliensis even at the highest concentration (256 M)
tilized in the assay for both of the protocols as indicated in Table 1.
onsidering that the incubation time could be inﬂuencing on the
eptide activity by its degradation, the Protocol II was used. This
rotocol was adapted from another assay to test the peptide KP,
lso used as control here, against P. brasiliensis in which the incu-
ation time was only for 12 h. The MIC  established for P. brasiliensis
solate Pb01 was 32 M and for Pb18 was 16 M.  However, even
able 1
he in vitro antifungal activity investigation of peptides selected from the transcriptome
b01  and Pb18. The minimum inhibitory concentration (MIC, M)  was investigated using
P1 P2 
Candida albicans 82 Mb 133 Mb
Paracoccidioides brasiliensis Pb01 N.D.a N.D.a
Paracoccidioides brasiliensis Pb18 N.D.a N.D.a
a N.D. = no detectable antifungal effect until 256 g ml−1 using both protocols.
b MIC  determined using protocol I and N.D. = activity not detected until 256 g ml−1.
c Obtained from another assay. Molecular weight (Da): P1 = 1756.12; P2 = 1918.20; P3 =P2,  P3, and P4 at concentration of 150 M and the antibiotic chloramphenicol (Cm)
at  185 M. *Statistically no difference was observed between P4 and Cm for E. coli.
1No inhibition was  detected in P1 for E. coli and S. aureus and P2 for E. coli. P ≤ 0.05.
with this short incubation time no antifungal activity was detected
for the predicted peptides against P. brasiliensis.
3.4. Bactericidal evaluation
The microdilution assay was performed in order to determine
the ability of the selected peptides from the genomes to kill or to
inhibit the growth of the Gram-negative bacteria E. coli and the
Gram-positive bacteria S. aureus.  According to Fig. 2, considering
the ability of all the peptides to kill or inhibit the growth of E. coli and
S. aureus,  the best activity was exhibited by the peptide P4 with the
inhibition of nearly 100% for E. coli and 60% for S. aureus at concen-
tration of 150 M.  The peptide P1 did not show any antimicrobial
activity against both bacteria tested and the peptide P2 showed
inhibition only for S. aureus (46%) at concentration of 133 M.  The
 of P. brasiliensis and from the human genome against C. albicans and P. brasiliensis
 two different protocols (as described in Section 2).
P3 P4 AMB  KP
N.D.b N.D.b 0.5 M 1 Mc
N.D.a N.D.a 0.5 M 32 M
N.D.a N.D.a 0.5 M 16 M
 1612.92; P4 = 1697.03; KP (killer peptide) = 998.47; AMB  (amphotericin B) = 924.08.
A.C. Amaral et al. / Peptides
Fig. 3. Antibacterial activity of peptide P4 at concentrations of 10, 75 and 150 M
against E. coli. At 150 M it was observed a 97% on growth inhibition, 86.6% at
75  M and 48% at 10 M.  Cell growth inhibition was estimated by measuring the
absorbance change at 595 nm each 30 min during 180 min. C+: positive control, LB
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bedium alone; C : negative control, chloramphenicol at concentration of 185 M.
olecular mass (Da): P1 = 1756.12; P2 = 1918.20; P3 = 1612.92; P4 = 1697.03; chlo-
amphenicol = 323.13.
eptide P3 exhibited antimicrobial inhibition of 66.8% for E. coli and
4% for S. aureus at concentration of 150 M for both peptides.
Fig. 3 shows the growth inhibition in function of time and con-
entration exposure of E. coli incubated with the peptide P4, which
resented the best antimicrobial activity against these two  bacte-
ia. For E. coli (Fig. 3), the P4 presented the same antibactericidal
ctivity (97.3%) observed for chloramphenicol, although in a small
eptide amount (150 M)  than used for this antibiotic (185 M).
oreover, at concentration of 10 M a 48.2% of growth inhibi-
ion was observed, using about twenty times less peptide than
ig. 4. Tridimensional models constructed by using Modeller and I-Tasser servers. All t
egatively charged and blue residues positively charged. Side chains are presented at stick
eptide, (B) P2 antifungal and antibacterial peptide, (C) P3 antibacterial peptide and (D) P4 
acteria are highlighted in gray. The structures were visualized and analyzed using Pymo 37 (2012) 301–308 305
antibiotic. For the S. aureus (data not show), as observed for E. coli,
the best antifungal activity was also obtained by the peptide P4 with
a growth inhibition of 60.7% at concentration of 150 M versus 95%
growth inhibition presented by the chloramphenicol at 185 M.  In
half of this concentration (75 M),  P4 presented a 42.8% of growth
inhibition.
3.5. Molecular modeling analyses
After the construction of models (Fig. 4) it was  observed that
all four peptides were structurally organized in -helix confor-
mation, as observed for several antimicrobial peptides previously
reported [10,28,45] and listed in the publicly available databases
such as Swissprot and TrEMBL (http://www.expasy.org/sprot/
sprot-top.html), AMSDd (http://www.bbcm.univ.trieste.it/∼tossi/
pag1.htm), APD (http://aps.unmc.edu/AP/main.html) and ANTIMIC
(http://research.i2r.a-star.edu.sg/Templar/DB/ANTIMIC/).  A
Procheck summary of all peptides showed that 100% of amino
acid residues are in most favorable region for helix formation
(Table 2). Structural differences between the template structures
and predicted three-dimensional structure of the peptides model
were calculated by superimposition of C traces and backbones
onto the templates structures. The RMSD values between the
structures experimentally resolved and modeled in silico, were
calculated for P1, P2, P3 and P4. C traces, and the main chain
atom were measured at 0.97, 0.59, 0.90 and 0.50 A˚ respectively.
The RMSD values and low variability among the experimental
structure templates and the structure modeled reﬂect conser-
vation in most regions and emphasize a similar folding pattern
among these antimicrobial peptides. This result indicated that the
constructed peptides model presented its amino acid residues of
the average of the observed parameters. On the other hand, the
structure of the lateral chains was  considered to be well located,
when compared with the experimental structures with the same
he models are represented in cartoon and surface demonstrating in red residues
 format. Residues involved with pathogen interaction were named. (A) P1 antifungal
antibacterial peptide models. Binding motifs that determine speciﬁc activity against
l program.
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Table 2
Physicochemical properties of peptides P1, P2, P3 and P4.
Peptides Sequence ( NH2) Molecular
mass (Da)
Total hydrophobic
ratio (%) a
Boman index
(kcal mol−1)b
Ramachandran
plot (%)c
C-scored TM-scored
P1 FLAKAVAKAAAKALAKAL 1755.13 77 −0.88 100 – –
P2 KAGLAFPVGRVHRLLRK 1917.21 47 1.71 100 – –
P3  GLARGLREASKALDR 1611.94 40 3.14 100 0.06 0.68 ± 0.12
P4  GLAKGIKEAAKALDKAL 1696.04 52 0.41 100 0.28 0.73 ± 0.11
a Percentage total of hydrophobic amino acid residues in the peptide.
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fIndex generated by Antimicrobial Peptide Database (APD) that indicate protein
c Percentage of the amino acid residues in favorable regions for secondary struct
d Value obtained through of I-TASSER server for protein structure predictions tha
esolution. Moreover, probable residues involved with pathogen
nteraction and their physicochemical properties will be discussed
elow.
. Discussion
The emerging incidence of antimicrobial resistance mechanisms
eveloped by microbial pathogens remains a serious worldwide
roblem to public health. This threat is increasing mainly in
mmunocompromised patients, including those with AIDS, under-
oing anticancer chemotherapy or therapy after organ transplants.
he opportunistic pathogenic fungi, such as Candida sp., can invade
arious tissues and cause systemic infections, which are considered
ife-threatening for the patient [12]. Also, the infectious diseases
aused by antibiotic-resistant bacteria have contributed to make
he situation worst, especially in those patients, for which the suc-
ess of treatment with currently available drugs is becoming less
fﬁcient [8,16,27]. Thus, there is an urgent need to develop alter-
ative antibiotic therapies to change this situation.
Antimicrobial peptides are attractive to be used as antimicrobial
gents since episodes of natural resistance episodes are rare and
hey could show low toxicity effects to the mammalian cells [23].
hese compounds can be obtained from a variety of sources, includ-
ng frog’s skin, vertebrate and invertebrate animals, plants and
icroorganisms, presenting a broad range of activity [6].  Despite
he inexorable source of peptides, their obtainment from identiﬁ-
ation to puriﬁcation is a very long and expensive approach.
Modern approaches used to identify antimicrobial peptides are
roposed to reduce the long-time identiﬁcation, extraction, puriﬁ-
ation and characterization of biologically active peptides from
atural sources [27,31].  One alternative methodology is to analyze
n silico genes and proteins from genomic databases to predict and
dentify amino acid sequences that share similarities and molecular
eatures with natural bioactive peptides, such as cationic residual
harge, which have potentially bioactive properties [4].
In this work, the in silico approach for identiﬁcation of antimi-
robial peptides was used. A computational program developed by
ur research group was carried out to identify peptide sequences
n the genomic databases of the fungus P. brasiliensis [15] and
n the human genome. This software identiﬁed, initially, thirteen
otential antimicrobial peptide sequences, of which the four most
romising, that attended the most criteria of the parameters used in
he software, two  from each databases (P2/P3 present in P. brasilien-
is and P1/P4 in the human genome), were selected and chemically
ynthesized for investigation of the antimicrobial activity.
The peptides were tested in vitro against the fungi C. albicans
linical isolate and P. brasiliensis,  isolates Pb01 and Pb18. Two of
he four selected peptides presented antifungal activity against C.
lbicans. The minimum inhibitory concentration (MIC) exhibited
y the peptide P1 was 82 M and for P2 was 133 M.  Despite the
act that the MIC  values obtained against this fungus were higher
han those observed for the antifungal amphotericin B (0.5 M)  or
or the antimicrobial peptide KP (1 M)  these peptide sequencesng potential [51].
rmation.
ased on multiple-threading alignments.
can still be used to develop new therapeutic agents [27,29].  None
of the peptides in the concentrations tested presented antifungal
activity for the fungus P. brasiliensis.  Probably, this could be due to
differences observed between these two  pathogens on the target of
these peptides or because of the P. brasiliensis cell wall complexity,
which could impede the peptide penetration.
In order to evaluate the antibacterial activity of the transcrip-
tome selected peptides, the microdilution assay was  used for S.
aureus and E. coli bacteria. Our present results demonstrate that
one of the synthesized peptides, P4, presented a high potential
to kill both Gram-positive and Gram-negative bacteria tested. The
P4 ability exhibited to inhibit the bacteria growth was superior to
that observed for the conventional antibiotic chloramphenicol. It
was necessary for 150 M of the P4 to exhibit the same antibacte-
rial activity elicited by chloramphenicol at 185 M concentration,
resulting in the use of less peptide than antibiotic. Moreover, the
peptides P2 and P3 also presented activity to inhibit the S. aureus
and E. coli growth, showing potential to be used as peptide model
to develop a potent antibiotic. Another important consideration
relies on the fact that, as demonstrated by the hemolytic study,
none of the peptides showed toxicity to mammalian cells. This
may  be an indication that, depending on the modiﬁcations made to
improve the peptides antimicrobial activity, the chances of devel-
oping toxic side effects in a possible therapy using these peptides
can be decreased.
Although the potent antibacterial activity for the peptides was
observed, they did not present the same effect against fungi. Only
two of the peptides, P1 and P2, showed antifungal properties
against C. albicans with MIC  value higher than those obtained for
the conventional drugs. Despite the disappointing fact, these pep-
tides should not be disregarded for future use. Due to the incidence
of microorganisms’ resistance to available therapy, these molecules
can be used as a basis for development of more efﬁcient molecules
[5,27]. Knowing their sequences, it is possible to make changes in
the primary structure envisioning increasing their potency.
A diverse set of synthetic modiﬁcations on known peptide
sequences have been done to increase their antimicrobial potency.
Structural changes on the buforin II increased its activity by the
substitution of only a single amino acid residue [35]. The halocidin
suchlike were designed and one of them, di-K19Hc emerged as the
most promising candidate for the development of a new antibiotic
against antibiotic-resistant bacteria, presenting both antifungal
and antibacterial properties [33,35].
Finally structural and functional relation was evaluated by in
silico theoretical analyses. In spite of all peptides showing helical
structure and also hydrophobic ratio values of spectra of 20–80%,
minor differences between them were evaluated here. Firstly,
similar values of hydrophobic ratio and peptides studied here
were observed in Antimicrobial Database (APD) for antibacterial,
antifungal, antiviral and anticancer peptides [46]. The P1 pep-
tide presented -helix conformation with the cationic residues of
lysine organized in line that favors a membrane-peptide interac-
tion, despite a surprising absence of antibacterial activity. These
ptides
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ata clearly show that the antibacterial activity could be related
ith other factors in addition to the presence of hydrophobic and
ationic residues in the surface. Otherwise, P1 showed a remark-
ble activity toward pathogenic yeasts (Table 2). These data could
e explained by the hydrophobic residues that are also exposed
n the structure surface such as Phe1, Leu2, Leu14, Val6, and Leu18,
hich could interact to membrane (Fig. 4). In Table 2 the P1 pep-
ide demonstrates a Boman index value of −0.88 kcal mol−1, which
s similar to aurein 2.5, an antifungal peptide from Litoria aurea and
itoria raniformis (−0.89 kcal mol−1), which shows antifungal activ-
ty toward Candida tropicalis, Candida kefyr, Candida krusei,  Candida
arapsilosis and Candida glabata [49]. This peptide clearly shows
he residues Leu2, Phe3, Iso5, Val6, Val9, Val10, Phe13 and Leu16 in
he structural surface, showing clear homology with P1 peptide
urface. Moreover, others aureins isoforms also presented similar
oman-Index with values ranging from −1.06 to 0.12 kcal mol−1,
einforcing that structures that yield similar Boman index values
ould present antifungal activity as observed for P1 peptide [38].
The P2 peptide presented a predominant -helix conformation
ith cationic residues of arginine (positions 10, 13 and 16), histi-
ine (position 12) and lysine (positions 1 and 17) exposed on the
urface in the C-terminal region (Fig. 4). On the other hand, the
ro7 break the helix formation causing a turn at C-termini region.
n opposite side hydrophilic residues some hydrophobic residues
re also exposed on surface such as Leu4, Phe6, Val8, Val11, and
eu15. Another interesting issue consists in the homology (88%)
f P2 with histone H2A.1 chain C of yeast nucleosome core struc-
ure [45]. The antimicrobial properties of histones have long been
ecognized despite their low activity [24]. Yonezawa and collabo-
ators [50] related that a structural motif of histone, which strongly
inds to DNA, may  be used as an antimicrobial peptide to bind to
ell membrane. Studies suggested that several phospholipid bind-
ng proteins (bovine lung annexins and human serum lipoproteins)
nd some peptides such as tachyplesin I can bind to DNA [50]. Other
esult that contributed showed that Boman index obtained for P2
1.71 kcal mol−1) showed similar values encountered for both anti-
ungal and antibacterial peptides as observed for heliomicin from
eliothis virescens with 1.74 kcal mol−1 [30]. Moreover Drosophila
elanogaster andropin and bovine lactoferricin B peptides pre-
ented Boman index ranging 0.55–2.75 kcal mol−1 that seems to
e more active against Gram-positive bacteria and fungi [25,39]
orroborating with data reported here.
The P3 peptide presented -helix conformation with cationic
nd anionic residues that were exposed on the surface and dis-
ributed at N- to C-termini. Some hydrophobic residues such as
eu2, Leu6, and Leu13 are also observed across multiple hydrophilic
esidues (Fig. 4). Boman index value for P3 was  3.14 kcal mol−1.
imilar results were encountered for antibacterial cecropin D-like
eptides from Manduca sexta, that presented spectra between 1.46
nd 3.29 kcal mol−1 [13]. Moreover, the P4 peptide presented an
-helix conformation extremely similar to P3, with cationic and
nionic residues exposed on the surface and distributed in line
avoring electrostatic interaction and hydrogen bounds. On the
ther hand, hydrophobic residues are also observed in N- and C-
erminal boundary such as Leu2, Iso6 and Leu13, Leu16. Firstly,
oman index value for P4 was 0.41. Esculentin and brevinins
ntimicrobial peptides form Rana esculenta presented similar prop-
rties (0.27–0.75 kcal mol−1) and also showed activity against
ram-positive and Gram-negative bacteria [40]. Moreover, stud-
es demonstrated that the antimicrobial activity is decreased when
eucines or isoleucines are changed for charged and glycine residues
1,43].In summary the peptides here presented showed several
hysico-chemical properties in common. However, the Val6 and
al8 residues observed in P1 and P2, respectively might be impor-
ant in interaction with fungi. Several studies demonstrate that an 37 (2012) 301–308 307
amidated valine residue at C-termini showed lethal effects against
fungi, as well as a broad spectrum of pathogenic microorganisms
[7].  Other physicochemical properties seem to be determinant for
antifungal activity such as total hydrophobic ratio. The peptide
P1 presented hydrophobic ratio of 77% and residues with positive
theoretical charge in pH 7.0 (data not shown). These results are
in accordance with biochemical properties obtained from family
of basic cysteine-rich plant antifungal proteins from Brassicaceae
sp. and the antifungal protein from Aspergillus giganteus with
60 and 39% hydrophobicity respectively [9,41]. Furthermore, the
P2, P3 and P4 peptides presented values of 47, 40 and 52% for
hydrophobic ratio, with a clear reduction in comparison with P1,
which could explain the reduction/and or absence of antifun-
gal activity. Curiously P2 peptide presented activity against fungi
and bacteria indicating the importance of the hydrophobicity, but
showing that other physic-chemical properties must be important
for activity and speciﬁcity. In this view 134 antibacterial pep-
tides randomly evaluated here (data not shown) were obtained in
antimicrobial peptides database showing that antibacterial pep-
tides present hydrophobic mean of 46 ± 12% and for charges 4 ± 3
[46] as observed for P2, P3 and P4 indicating that hydrophobicity
ratio is also important for bactericidal activity.
On the other hand, another question was drawn. Why  were
P3 and P4 unable to reduce fungal development? Several theories
could be proposed but the presence of binding motifs (RE, DR, KE
and DK) in P3 and P4 peptides could shed some light over this issue.
These binding motifs are observed in various anionic antibacterial
peptides that did not show antifungal activity as well as chromacin,
peptide B and enkelytin from bovine and thymosin-4 and LEK pep-
tides family from Homo sapiens [20], leading us to believe that the
presence of a cationic residue followed by an anionic one could be
important for microorganism selection. Nevertheless studies utiliz-
ing mutant peptides could elucidate the importance of those motifs
observed here.
5. Conclusions
In conclusion, our results suggest that the development of
antimicrobial peptides from genomic databases is an alterna-
tive strategy to abbreviate achievement of peptides from natural
resources. Even those sequences that do not show effective activity
in the ﬁrst instance, can still be structurally modiﬁed to obtain more
efﬁcient antimicrobial molecules. Finally, structural in silico stud-
ies suggested that the presence of interactive ionic binding motifs
(charges 4 ± 3), in addition to leucines and isoleucines which could
contribute to hydrophobic ratio (around 46 ± 12%), may  increase
the speciﬁc activity for bacteria, playing an important role in the
interaction with bacterial membranes.
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